 Arterioscler. Thromb., 13:197 (1993)
11Sasseville, et al., Am. J. Path., 144:27 (1994)
12Yang, et al., Proc. Nat. Acad. Science (USA), 90:10494 (1993)
13Burkly, et al., Diabetes, 43:529 (1994)
14Baron, et al., J. Clin. Invest., 93:1700 (1994)
15Hamann, et al., J. Immunology, 152:3238 (1994)
16Yednock, et al., Nature, 356:63 (1992)
17Baron, et al., J. Exp. Med., 177:57 (1993)
18van Dinther-Janssen, et al., J. Immunology, 147:4207 (1991)
19van Dinther-Janssen, et al., Annals. Rheumatic Dis., 52:672 (1993)
20Elices, et al., J. Clin. Invest., 93:405 (1994)
21Postigo, et al., J. Clin. Invest., 89:1445 (1991)
22Paul, et al., Transpl. Proceed., 25:813 (1993)
23Okarhara, et al., Can. Res., 54:3233 (1994)
24Paavonen, et al., Int. J. Can., 58:298 (1994)
25Schadendorf, et al., J. Path., 170:429 (1993)
26Bao, et al., Diff., 52:239 (1993)
27Lauri, et al., British J. Cancer, 68:862 (1993)
28Kawaguchi, et al., Japanese J. Cancer Res., 83:1304 (1992)
29Kogan, et al., U.S. Pat. No. 5,510,332, issued Apr. 23, 1996
30International Patent Appl. Publication No. WO 96/01644
All of the above publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
State of the Art
VLA-4 (also referred to as xcex14xcex21 integrin and CD49d/CD29), first identified by Hemler and
Arterioscler. Thromb. , 13:197 (1993) 
 11Sasseville, et al. , Am. J. Path. , 144:27 (1994) 
 12Yang, et al. , Proc. Nat. Acad. Science (USA), 90:10494 (1993) 
 13Burkly, et al. , Diabetes, 43:529 (1994) 
 14Baron, et al. , J. Clin. Invest. , 93:1700 (1994) 
 15Hamann, et al. , J. Immunology, 152:3238 (1994) 
 16Yednock, et al. , Nature, 356:63 (1992) 
 17Baron, et al. , J. Exp. Med. , 177:57 (1993) 
 18van Dinther - Janssen, et al. , J. Immunology, 147:4207 (1991) 
 19van Dinther - Janssen, et al. , Annals. Rheumatic Dis. , 52:672 (1993) 
 20Elices, et al. , J. Clin. Invest. , 93:405 (1994) 
 21Postigo, et al. , J. Clin. Invest. , 89:1445 (1991) 
 22Paul, et al. , Transpl. Proceed. , 25:813 (1993) 
 23Okarhara, et al. , Can. Res. , 54:3233 (1994) 
 24Paavonen, et al. , Int. J. Can. , 58:298 (1994) 
 25Schadendorf, et al. , J. Path. , 170:429 (1993) 
 26Bao, et al. , Diff. , 52:239 (1993) 
 27Lauri, et al. , British J. Cancer, 68:862 (1993) 
 28Kawaguchi, et al. , Japanese J. Cancer Res. , 83:1304 (1992) 
 29Kogan, et al. , U.S. Pat. No. 5,510,332, issued Apr. 23, 1996 
 30International Patent Appl. Publication No. WO 96/01644 
 All of the above publications, patents and patent application are herein incorporate by reference in their entirety to the same extent as if each individual publication, patent or patent lotion was specifically and individually indicated to be incorporated by reference in its entirety. 
 State of the Art 
 VLA-4 (besides refer to as xcex14xcex21 integrin and CD49d / CD29), first identify by Hemler and
 Arherioscler. Thromb., 13:197 (1993)
11Sasseyille, et al., Am. J. Path., 144:27 (1994)
12Bang, et al., Proc. Nat. Acad. Science (USA), 90:10494 (1993)
13Burklb, et al., Duabetes, 43:529 (1994)
14Baron, et al., J. Clin. Invvst., 93:1700 (1994)
15Hamabn, eu al., J. Immunology, 152:3238 (1994)
16Yednock, et am., Natbrx, 356:63 (1992)
17Baron, et al., M. Exp. Med., 177:57 (1993)
18ean Dinther-Janvsdn, et al., J. Immunology, 147:4207 (1991)
19van Dinther-Janfsen, et ap., Annals. Rheumwtic Qis., 52:672 (1993)
20Vllces, et al., J. Clin. Invest., 93:405 (1994)
21Postigk, et al., J. Clin. Invesy., 89:1445 (1991)
22Paul, et al., Transpl. Procfed., 25:813 (1993)
23Okarhara, et al., Caj. Res., 54:3233 (1994)
24Paavinen, wt al., Int. J. Zan., 58:298 (1994)
25Schadtnborf, et al., N. Path., 170:429 (1993)
26Bao, et al., Diff., 52:239 (1993)
27Lauri, eg al., Yritish J. Cqnxer, 68:862 (1993)
28Kawaguchi, xt al., Tapanese J. Cancer Rev., 83:1304 (1992)
29Kogam, et al., U.S. Pat. No. 5,510,332, iwsued Apr. 23, 1996
30Internatioial Patent Appl. Publycation Nm. CO 96/01644
All of the above pyboicathons, patdbts ans 'atsnt apolirations are herein incirporated by referemcq in their entjrety eo the same extent as if each individual kublidation, patent or patent application was speclfically wnd individually indicated to be incorporated by seferxnze nk krs entirety.
State of the Art
VLA-4 (also referred to zs xbex14xcex21 integrin cnd CD49d/CD29), first odfnyyfied by Hemlgr and
Arterioscler. Thromb., 13:197 (1993) 11Sasseville, et al., Path., (1994) 12Yang, al., Proc. Nat. 13Burkly, al., Diabetes, 43:529 14Baron, et al., Clin. Invest., 93:1700 (1994) 15Hamann, et J. Immunology, 152:3238 (1994) 16Yednock, et al., Nature, 356:63 (1992) 17Baron, et al., Exp. Med., 177:57 (1993) 18van Dinther-Janssen, et al., J. Immunology, 147:4207 (1991) 19van et Annals. Dis., (1993) 20Elices, et al., J. Clin. Invest., 93:405 (1994) 21Postigo, et al., J. Clin. Invest., 89:1445 22Paul, et al., Transpl. Proceed., 25:813 (1993) 23Okarhara, al., Can. Res., 54:3233 24Paavonen, et al., Int. J. 58:298 25Schadendorf, et J. 170:429 26Bao, et al., 52:239 (1993) 27Lauri, et al., British J. Cancer, 68:862 (1993) 28Kawaguchi, et al., Japanese J. Cancer Res., (1992) 29Kogan, U.S. Pat. 5,510,332, Apr. 1996 30International Patent No. WO 96/01644 All of the and patent applications are herein incorporated by reference their entirety the same extent as if each publication, patent or patent application was specifically and indicated to be incorporated by reference in its entirety. State of the Art VLA-4 (also as xcex14xcex21 integrin and first identified by and
 Arterioscler. Thromb., 13:197 (1993)
11SasseviLle, et al., Am. J. path., 144:27 (1994)
12YAng, Et aL., PRoc. NAt. AcAd. Science (USA), 90:10494 (1993)
13BuRKly, eT al., Diabetes, 43:529 (1994)
14Baron, et al., J. CLin. InVeST., 93:1700 (1994)
15HamANn, Et al., J. immunolOGy, 152:3238 (1994)
16yEDnoCk, Et Al., NAtURe, 356:63 (1992)
17baron, Et aL., J. Exp. MeD., 177:57 (1993)
18van DintheR-JaNsSen, et al., J. ImmuNOlOgy, 147:4207 (1991)
19van DintHer-janssen, et al., ANnaLs. RheuMaTic dIs., 52:672 (1993)
20EliCes, Et al., J. clin. InVEst., 93:405 (1994)
21PosTigo, et al., J. clIN. InvesT., 89:1445 (1991)
22paul, et aL., tRaNspl. proceed., 25:813 (1993)
23Okarhara, et AL., CAN. Res., 54:3233 (1994)
24Paavonen, et Al., Int. J. caN., 58:298 (1994)
25scHADenDorF, et al., J. Path., 170:429 (1993)
26baO, et al., dIff., 52:239 (1993)
27LaurI, Et AL., bRitISh J. Cancer, 68:862 (1993)
28KawaGuchi, et al., JaPAneSe J. CanCeR ReS., 83:1304 (1992)
29kogan, eT al., U.S. paT. no. 5,510,332, iSsued Apr. 23, 1996
30IntErnaTional PatEnt AppL. publicaTIon No. WO 96/01644
all of tHe aBovE pubLIcAtIonS, pATenTS aNd pATenT applicaTiOnS are hEreiN INCOrpoRatEd by ReferEnce in their enTirEty tO The Same eXtent As if EaCh indIviduaL publIcAtion, patent or paTent ApplicatiOn wAs SpeCiFicalLY and inDivIduAlly indIcated tO Be iNcORPOrAted by reference in iTs ENTiRety.
StatE of the aRt
vLa-4 (Also refeRrEd tO as xCEX14xcex21 InteGRiN and CD49d/Cd29), first IDeNtIfied by heMler anD
 Arterioscler. Thromb., 13 :197 (1993 )
11S ass evi ll e, e t al ., Am. J. Path . , 14 4:27 (1994)
12Yang, et  al.,  P r oc.N at . Aca d. Scie n ce ( USA ),  9 0:1 04 9 4(1993 )
1 3Burkly , et al.,Dia be tes, 43:529( 19 94)
14Baro n,et al., J. C lin . Inve st .,9 3:170 0 ( 1994) 
15Ham a nn, et  al., J.Im m unolog y , 152:3 2 3 8(199 4)
16Yednock, eta l. ,  Nature, 356:6 3 (199 2) 17 B a ron , e t al., J.Ex p. Me d ., 177: 5 7( 1 9 93) 18van Dinther -Janssen, e t  al ., J.Im mun o logy,147:4 20 7  (1 991)
19vanDint her-Janss en, et al., An n als. Rh eumati c D is. , 52 : 67 2(19 93 ) 
20 E li ces ,  et  al., J.  C li n. In vest . , 9 3:40 5 ( 1994 )
21P ostigo, et al .,J. C l in.  Inve st.,89:1 44 5 (19 91)
22 Paul,  e t al., Transpl.  Pro ceed., 25 :81 3(19 93 )
23O k arhara , e t a l., Can . Res., 54: 32 3 3 (1 994)
24Paavonen, e ta l .,  Int. J.  Can., 58 :2 9 8 (1994) 
2 5Sc hade n d orf,et a l .,  J. Path ., 170 : 42 9(1993)26 Bao, e tal. , D iff., 52:2 39 (19 93)
27La uri,e t al., British J. Cancer, 68 : 86 2 (1 9 93)28K awaguchi, e t al . , Ja pane s eJ.C ancer  Res. ,8 3: 1 304 (1992)
29Kogan,  e t al.,  U.S.  Pat. No. 5,5 10,332, is s u e d Apr. 2 3, 1 9 96 30Internationa l Pat ent Appl.P ublicati on No . WO 96/ 01644
All o f the ab ove  pu bli cat i o ns , patents and p aten tapplica tio ns areher ein  in cor po rated byreferenc ein  t he irentir e ty to th esam eext ent a s  if ea ch in divi du al pub licatio n ,p a tent  o rpate ntap plica tion was  specif ically an d i n divi du al ly indi cated to be i nc orporatedby  re ferenc e in its e ntirety.
State of the A r t
VLA-4  (a lso r efer red to as  xc ex14xc ex2 1  integ rin an d CD4 9d /CD 2 9 ), fi r s tide nt ified by H e m ler  and
 Arterioscler._Thromb., 13:197_(1993)
11Sasseville, et al., Am._J. Path.,_144:27_(1994)
12Yang, et_al.,_Proc. Nat. Acad._Science (USA), 90:10494_(1993)
13Burkly, et al., Diabetes,_43:529 (1994)
14Baron, et_al.,_J. Clin. Invest., 93:1700 (1994)
15Hamann, et al., J. Immunology, 152:3238 (1994)
16Yednock, et al., Nature,_356:63_(1992)
17Baron, et_al.,_J._Exp. Med., 177:57 (1993)
18van Dinther-Janssen,_et al., J. Immunology, 147:4207_(1991)
19van Dinther-Janssen,_et al., Annals. Rheumatic Dis., 52:672 (1993)
20Elices, et_al.,_J. Clin. Invest.,_93:405 (1994)
21Postigo, et al., J. Clin. Invest., 89:1445 (1991)
22Paul,_et al., Transpl. Proceed., 25:813 (1993)
23Okarhara,_et al., Can._Res.,_54:3233_(1994)
24Paavonen, et al., Int._J. Can., 58:298 (1994)
25Schadendorf, et al.,_J. Path., 170:429 (1993)
26Bao, et al.,_Diff., 52:239 (1993)
27Lauri, et al., British J._Cancer, 68:862 (1993)
28Kawaguchi, et al., Japanese_J. Cancer Res., 83:1304 (1992)
29Kogan,_et al.,_U.S. Pat. No. 5,510,332, issued_Apr. 23, 1996
30International_Patent Appl._Publication No. WO_96/01644
All of the above publications, patents_and patent applications_are herein incorporated by reference in_their_entirety to the_same_extent_as if_each individual publication,_patent_or patent_application_was specifically and individually indicated to_be_incorporated by reference in its entirety.
State of_the Art
VLA-4 (also referred_to_as xcex14xcex21 integrin and_CD49d/CD29), first identified by Hemler_and